Susan D. Wyrick - 02 Jan 2025 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role: Acting Chief Financial Officer and Principal Accounting Officer
Signature: /s/ Julie Shah, Attorney-in-Fact for Susan D. Wyrick
Issuer symbol: SANA
Transactions as of: 02 Jan 2025
Net transactions value: -$2,584
Form type: 4
Filing time: 03 Jan 2025, 16:15:57 UTC
Previous filing: 05 Dec 2025
Next filing: 03 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SANA	Common Stock	Options Exercise	$0	+5,000	+3.3%	$0.000000	155,512	02 Jan 2025	Direct	F1
transaction	SANA	Common Stock	Tax liability	$2,584	-1,566	-1%	$1.65	153,946	02 Jan 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SANA	Restricted Stock Units	Options Exercise	$0	-5,000	-40%	$0.000000	7,500	02 Jan 2025	Common Stock	5,000		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 3,000 shares acquired on November 15, 2024 pursuant to Sana Biotechnology, Inc.'s ("Sana") 2021 Employee Stock Purchase Plan.
F2	Each restricted stock unit represents a contingent right to receive one share of Sana common stock.
F3	The award vested as to 40% of the restricted stock units on January 2, 2025 and the remaining 60% of the restricted stock units will vest on January 2, 2026, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

Remarks:

Acting Chief Financial Officer and Principal Accounting Officer